Ameriprise’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $340K | Buy |
106,660
+2,734
| +3% | +$11.1K | ﹤0.01% | 3792 |
|
|
2026
Q1 | $458K | Sell |
103,926
-284,352
| -73% | -$1.54M | ﹤0.01% | 3621 |
|
|
2025
Q4 | $2.47M | Buy |
388,278
+4,915
| +1% | +$34.2K | ﹤0.01% | 2884 |
|
|
2025
Q3 | $3.58M | Buy |
383,363
+159,054
| +71% | +$1.61M | ﹤0.01% | 2663 |
|
|
2025
Q2 | $3.23M | Sell |
224,309
-71,844
| -24% | -$709K | ﹤0.01% | 2683 |
|
|
2025
Q1 | $2.04M | Sell |
296,153
-33,835
| -10% | -$213K | ﹤0.01% | 2888 |
|
|
2024
Q4 | $1.75M | Buy |
329,988
+224,399
| +213% | +$1.23M | ﹤0.01% | 3000 |
|
|
2024
Q3 | $385K | Buy |
105,589
+85,499
| +426% | +$269K | ﹤0.01% | 3571 |
|
|
2024
Q2 | $54.8K | Buy |
+20,090
| New | +$67.2K | ﹤0.01% | 3812 |
|
|
2023
Q1 | – | Sell |
-17,517
| Closed | -$29K | – | 4045 |
|
|
2022
Q4 | $29K | Sell |
17,517
-17,867
| -50% | -$28.3K | ﹤0.01% | 3884 |
|
|
2022
Q3 | $44K | Sell |
35,384
-10,300
| -23% | -$16.6K | ﹤0.01% | 3897 |
|
|
2022
Q2 | $76K | Sell |
45,684
-5,015
| -10% | -$9.81K | ﹤0.01% | 3808 |
|
|
2022
Q1 | $125K | Sell |
50,699
-185
| -0.4% | -$505 | ﹤0.01% | 3823 |
|
|
2021
Q4 | $190K | Sell |
50,884
-13,150
| -21% | -$71K | ﹤0.01% | 3796 |
|
|
2021
Q3 | $401K | Sell |
64,034
-385
| -0.6% | -$3.17K | ﹤0.01% | 3475 |
|
|
2021
Q2 | $635K | Buy |
64,419
+36,275
| +129% | +$316K | ﹤0.01% | 3374 |
|
|
2021
Q1 | $263K | Buy |
28,144
+14,160
| +101% | +$112K | ﹤0.01% | 3636 |
|
|
2020
Q4 | $67K | Hold |
13,984
| – | – | ﹤0.01% | 3713 |
|
|
2020
Q3 | $56K | Hold |
13,984
| – | – | ﹤0.01% | 3670 |
|
|
2020
Q2 | $64K | Sell |
13,984
-5
| -0% | -$22 | ﹤0.01% | 3609 |
|
|
2020
Q1 | $46K | Sell |
13,989
-95
| -0.7% | -$365 | ﹤0.01% | 3586 |
|
|
2019
Q4 | $61K | Hold |
14,084
| – | – | ﹤0.01% | 3665 |
|
|
2019
Q3 | $55K | Hold |
14,084
| – | – | ﹤0.01% | 3664 |
|
|
2019
Q2 | $65K | Buy |
+14,084
| New | +$60.1K | ﹤0.01% | 3681 |
|
|
2018
Q4 | – | Sell |
-14,827
| Closed | -$64K | – | 3782 |
|
|
2018
Q3 | $64K | Buy |
14,827
+500
| +3% | +$2.15K | ﹤0.01% | 3651 |
|
|
2018
Q2 | $53K | Buy |
14,327
+2,500
| +21% | +$9.5K | ﹤0.01% | 3601 |
|
|
2018
Q1 | $50K | Buy |
11,827
+275
| +2% | +$1.44K | ﹤0.01% | 3586 |
|
|
2017
Q4 | $68K | Buy |
+11,552
| New | +$62.4K | ﹤0.01% | 3585 |
|
|
2017
Q1 | – | Sell |
-11,755
| Closed | -$39K | – | 3691 |
|
|
2016
Q4 | $39K | Buy |
+11,755
| New | +$31.9K | ﹤0.01% | 3813 |
|
Other funds holding NAGE
SW
TCM
Ameriprise's NAGE Position: Q2 2026 in Review
Ameriprise increased its Niagen Bioscience (NAGE) stake by 2.6% in Q2 2026, buying an estimated $11.1K and bringing the position to 106,660 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #3792.
Ameriprise first reported a position in NAGE in Q4 2016 and has held it in 29 quarters since. The position peaked at $3.58M in Q3 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.
- Ameriprise held 106,660 shares of Niagen Bioscience worth $340K as of Q2 2026.
- Ameriprise bought 2,734 Niagen Bioscience shares in Q2 2026, an estimated $11.1K.
- Niagen Bioscience made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3792 holding.
- Ameriprise first reported a position in Niagen Bioscience in Q4 2016 and has held it in 29 quarters since.
- Ameriprise's Niagen Bioscience position peaked at $3.58M in Q3 2025.
- 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.
Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.